First Header Logo Second Header Logo

Connection

Waldemar Debinski to Glioma

This is a "connection" page, showing publications Waldemar Debinski has written about Glioma.
Connection Strength

2.612
  1. Rossmeisl JH, Herpai D, Quigley M, Cecere TE, Robertson JL, D'Agostino RB, Hinckley J, Tatter SB, Dickinson PJ, Debinski W. Phase I trial of convection-enhanced delivery of IL13RA2 and EPHA2 receptor targeted cytotoxins in dogs with spontaneous intracranial gliomas. Neuro Oncol. 2021 03 25; 23(3):422-434.
    View in: PubMed
    Score: 0.683
  2. Ferluga S, Debinski W. Ephs and Ephrins in malignant gliomas. Growth Factors. 2014 Dec; 32(6):190-201.
    View in: PubMed
    Score: 0.440
  3. Debinski W. Personalized, multivalent, and more affordable: the globalization of vaccines. Clin Cancer Res. 2005 Aug 15; 11(16):5663-4.
    View in: PubMed
    Score: 0.231
  4. Debinski W, Gibo DM. Fos-related antigen 1 modulates malignant features of glioma cells. Mol Cancer Res. 2005 Apr; 3(4):237-49.
    View in: PubMed
    Score: 0.225
  5. Mintz A, Gibo DM, Madhankumar AB, Debinski W. Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma. J Neurooncol. 2003 Aug-Sep; 64(1-2):117-23.
    View in: PubMed
    Score: 0.201
  6. Mintz A, Gibo DM, Slagle-Webb B, Christensen ND, Debinski W. IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia. 2002 Sep-Oct; 4(5):388-99.
    View in: PubMed
    Score: 0.189
  7. Sharma P, Debinski W. Receptor-Targeted Glial Brain Tumor Therapies. Int J Mol Sci. 2018 Oct 25; 19(11).
    View in: PubMed
    Score: 0.144
  8. Renfrow JJ, Soike MH, Debinski W, Ramkissoon SH, Mott RT, Frenkel MB, Sarkaria JN, Lesser GJ, Strowd RE. Hypoxia-inducible factor 2a: a novel target in gliomas. Future Med Chem. 2018 09 01; 10(18):2227-2236.
    View in: PubMed
    Score: 0.142
  9. McTyre E, Lucas JT, Helis C, Farris M, Soike M, Mott R, Laxton AW, Tatter SB, Lesser GJ, Strowd RE, Lo HW, Debinski W, Chan MD. Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide. Am J Clin Oncol. 2018 08; 41(8):813-819.
    View in: PubMed
    Score: 0.142
  10. Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AK, Puntel M, Foulad D, Zadmehr A, Ahlzadeh GE, Kroeger KM, Tesarfreund M, Lee S, Debinski W, Sareen D, Svendsen CN, Rodriguez R, Lowenstein PR, Castro MG. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci U S A. 2010 Nov 16; 107(46):20021-6.
    View in: PubMed
    Score: 0.083
  11. Madhankumar AB, Mintz A, Debinski W. Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2. Neoplasia. 2004 Jan-Feb; 6(1):15-22.
    View in: PubMed
    Score: 0.052
  12. Madhankumar AB, Mintz A, Debinski W. Alanine-scanning mutagenesis of alpha-helix D segment of interleukin-13 reveals new functionally important residues of the cytokine. J Biol Chem. 2002 Nov 08; 277(45):43194-205.
    View in: PubMed
    Score: 0.047
  13. Ivey JW, Latouche EL, Richards ML, Lesser GJ, Debinski W, Davalos RV, Verbridge SS. Enhancing Irreversible Electroporation by Manipulating Cellular Biophysics with a Molecular Adjuvant. Biophys J. 2017 Jul 25; 113(2):472-480.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.